To treat atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.

‘To treat atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding. This device prevents blood clots from forming in the left atrial appendage and therefore prevents stroke.’

It has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding. To assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL. 




The researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial. "What we know is that the PROTECT AF trial enrolled more patients and has longer follow-up at this time and this allows greater statistical certainty," said Dr. James Freeman, assistant professor of cardiology and first author on the paper. "Based on that, the study may provide more certainty in terms of cost-effectiveness." However, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.
The study published online in Circulation: Arrhythmia and Electrophysiology.
Source-Eurekalert